21 results about "Tumour development" patented technology

The invention discloses a tumor evolution trajectory prediction method and system based on image feature learning, and the method comprises the steps: obtaining the whole-process pathological section image data of a target type tumor patient, carrying out the analysis and screening of the image quality, constructing a pathological section screening strategy, and extracting a standard image; extracting tumor cell characteristics based on the standard image, performing grouping analysis on the cell characteristics of different time periods through a clustering algorithm, and determining tumor cell development characteristics; further constructing the cell development characteristics of multiple patients into a heterogeneity propagation network, simulating the tumor evolution process by using a random walk algorithm, and identifying the multi-branch evolution trajectory of the tumor; and finally, establishing a tumor evolution trajectory prediction model to predict the tumor development trend of the current patient. According to the method, the accuracy and interpretability of tumor evolution trajectory modeling can be improved, and reliable support is provided for clinical individualized diagnosis and treatment.

The invention relates to the technical field of medical image processing, in particular to a tumor development analysis method and system based on image recognition. The method comprises the following steps: acquiring a multi-temporal tumor image data set, analyzing the multi-temporal tumor image data set, and determining spatial probabilistic boundary representation information; according to the spatial probabilistic boundary representation information, performing multi-dimensional feature fusion analysis on the tumor boundary, and determining tumor development situation feature information; performing analogue simulation on the tumor development situation according to the tumor development situation feature information, and determining tumor development risk information; and analyzing the tumor development risk information, and determining and outputting dynamic follow-up visit suggestion information. According to the method and the device, the spatial probabilistic boundary representation information is constructed, so that the misjudgment on the tumor boundary caused by binarization decision due to the forced closed contour tendency of an image recognition algorithm is avoided, the boundary illusion generated when the tumor boundary is analyzed in the prior art is effectively eliminated, and the evaluation accuracy of the tumor development situation is improved.

The invention provides a tumor immunodiagnosis and treatment drug AC484-PFC and a preparation method and application thereof, the tumor immunodiagnosis and treatment drug AC484-PFC comprises a drug-loading membrane, glycerin and a perfluorinated compound PFC are wrapped in the drug-loading membrane, and the drug-loading membrane comprises AC484, phospholipid and cholesterol. The medicine has the characteristics of high stability and strong medicine carrying capacity, and can be delivered to tumor tissues through multiple ways such as respiratory tracts or veins. The AC484-PFC prepared by the invention is dynamically monitored through a 1H / 19F magnetic resonance imaging technology, the accumulation and distribution of drugs in a living body are evaluated in real time, in-vivo and non-invasive evaluation of a tumor development state is supported, immunotherapy is accurately guided, and the tumor treatment effect is remarkably improved.

Gene amplifications are an oncogenic driver utilized by many forms of cancer in tumor development or treatment relapse. Promoting genomic instability or the proclivity to propagate genomic alterations through acquired defects in DNA repair machinery, replication licensing, or cell cycle control, gene amplifications not only drive oncogenesis, but also afford an opportunity for therapeutic exploitation. Here, CRISPR-Cas9 nickases are disclosed which selectively promote cancer cell death in a gene amplification-dependent manner. For example, CRISPR- Cas9 nickases generate a lethal number of highly toxic single-ended double-strand breaks within the genome of proliferating cancer cells harboring amplified genomic loci during DNA replication. Cas9 nickases may serve as a tumor-selective therapeutic that mitigates the collateral damage observed with conventional chemoradiotherapies and avoids chemoresistance.

The research provides application of 7,2'-dihydroxy-3',4'-dimethoxyisoflavan in preparation of anticancer drugs, and belongs to the technical field of medicine.The pharmacodynamic experiment result of the application shows that 7,2'-dihydroxy-3',4'-dimethoxyisoflavan can inhibit M2 type (tumor development promotion) polarization of breast cancer cells (4T-1) induced mouse peritoneal macrophages (RAW264.7) in vitro, and then play an anti-tumor role; in vivo experiment, 7,2'-dihydroxy-3',4'-dimethoxyisoflavan has obvious therapeutic effect on breast cancer animal model, and can be used for preparation of anticancer drugs.

The invention relates to the technical field of biological medicine. The invention provides an application of bifidobacterium breve lw01 in preparation of a product for prevention or adjuvant therapy of obesity-related tumors, and also provides an application of the bifidobacterium breve lw01 in a product for regulating intestinal flora and bile acid metabolism level. In the invention, bile acid (such as taurocholic acid TCA) is used as an intervention target, and the bifidobacterium breve lw01 is used for targeted regulation of disordered bile acid metabolism in an obesity state, so that the promotion effect of obesity on tumor growth is remarkably relieved, and finally, the purpose of inhibiting the development of obesity-related tumors is achieved.

The invention discloses an application of TCF7L2 (T cell factor 7L2) in treatment of glioblastoma. The research shows that the transcription factor TCF7L2 has an important tumor inhibition effect in glioblastoma cells (GBM), and the deletion of the transcription factor TCF7L2 can obviously accelerate the growth and malignant progression of tumor cells, so that the response capability of the GBM cells to exogenous neural signals is enhanced, and the tumor development is further promoted. In mechanism, the TCF7L2 regulates and controls the expression of various neurotransmitter receptors, and inhibitors applying the receptors can effectively reverse tumor promoting phenotypes caused by deletion of the TCF7L2, so that the TCF7L2 plays a key role in inhibiting GBM nerve dependence progression by maintaining the steady state of neural signal related receptors. The invention provides a new diagnostic and prognostic marker and a new therapeutic target for treatment of GBM, and provides a new thought and a new strategy for treatment of GBM.

The application relates to a target point recognition device, method, apparatus, computer readable storage medium and computer program product, relates to the technical field of biological information, and can improve the effectiveness of a target point recognition result. The target point recognition device is configured to perform the following steps: determining a candidate biological molecule in tumor cells that can provide an action target point for a targeted drug; performing expression level prediction on the candidate biological molecule by a trained expression prediction model, determining expression levels of the candidate biological molecule at multiple development stages of a tumor according to a prediction result; determining a first importance detection result of the candidate biological molecule in a tumor development process according to the expression levels of the candidate biological molecule at the multiple development stages of the tumor; and judging whether a drug action target point is determined according to the candidate biological molecule according to a tumor specificity detection result of the candidate biological molecule and the first importance detection result.

The invention provides a nano-drug delivery platform of a metal organic framework based on Zn / Co-MOF as well as a preparation method and application of the nano-drug delivery platform, and belongs to the technical field of biology and new medicine. The nano-drug delivery platform based on the Zn / Co-MOF metal organic framework comprises a Zn / Co-MOF metal organic framework core, an organic drug composition loaded on the surface of the core and in micropores, and a homologous tumor cell membrane wrapping the outermost layer, wherein the organic pharmaceutical composition is prepared from a tamoxifen-cis-platinum dimer prodrug, a photo-thermal therapeutic agent IR-820 and an immunomodulator metformin. The nano-drug delivery platform provided by the invention visually monitors tumor development and treatment processes in vivo through fluorescence luminescence, integrates chemotherapy-photothermal-endocrine three modes into a whole, has good safety and biocompatibility, shows a remarkable anti-tumor effect in a tumor-bearing nude mouse model, and has good application prospects. And a brand new strategy is provided for treatment of ER + breast cancer.

This patent discloses a method for detecting a patient's tumor burden. DNA is extracted from a patient's tumor tissue sample, a predetermined number of biomarker genes are selected to form a biomarker gene cluster ("customized gene cluster"). A DNA sample of circulating free cells in the patient's body fluid is isolated. DNA sequences containing biomarker genes are enriched in the free DNA fragments. The enriched DNA is sequenced. The mutant and normal DNA sequences in the enriched DNA are counted. The patient's tumor burden is then determined. Preferably, mutations in therapeutically relevant genes ("drug-targeted genes") are detected simultaneously with the detection of the customized gene cluster.

The application provides a mouse fertilized ovum, wherein a sequence shown in SEQ ID NO. 1 in the fifth exon of a Trp53 gene is replaced by a fluorescent protein gene, and the individual developed from the fertilized ovum is a transgenic mouse for in-vivo labeling of p53 protein, and a construction method of the aforementioned fertilized ovum and transgenic mouse is provided. Through expression of the p53 and fluorescent label fusion protein, the application realizes accurate in-vivo labeling of the p53 protein, directly reflects the level of the p53 protein, and can track and analyze and sort abnormal cells by using flow cytometry according to the fluorescent protein label, so as to realize analysis and monitoring of tumor cell characteristics and tumor development process.

The invention belongs to the technical field of medicine application, and particularly relates to a medicine for reversing tumor multidrug resistance. The AMPK signal channel serves as an energy sensing center, and the expression mode of the catalytic subunit PRKAA1 / 2 of the AMPK signal channel has dispute in TNBC. Previous researches show that the AMPK activity in primary breast cancer is generally reduced, and clinical data analysis shows that the AMPK expression of a patient with advanced TNBC is increased and is related to poor prognosis. The invention finds that the expression of PRKAA2 in primary TNBC tissue is reduced, but DOX treatment can induce the expression of PRKAA2, and the expression of PRKAA2 is obviously increased in drug-resistant TNBC cells and TBCSCs. Mechanism research shows that the dynamic expression regulation is derived from CTED2 dependent CBP / p300 mediated H3K27 acetylation modification. The result shows that the AMPK signal has space-time specificity in TNBC, and the function of the AMPK signal may depend on the tumor development stage and the cell subtype.

This invention relates to the field of gene diagnostic technology, and in particular to the application of polymethylation site combination in the preparation of products for detecting, predicting or monitoring tumor development. This invention is the first to combine the detection of specific methylation sites of the SFRP2 gene with the detection of specific methylation sites of the SDC2 gene, and use it in the preparation of products for detecting, predicting or monitoring tumor development. Compared with the prior art, this invention (1) uses a set of primers and probes that correspond to only one specific methylation site, avoiding the instability of specificity and sensitivity that occurs in the prior art; (2) this invention combines the specific methylation sites of the SFRP2 gene with the specific methylation sites of the SDC2 gene for detection, which significantly improves the detection sensitivity and specificity.

The present application relates to the technical field of gene diagnosis, in particular to the application of SFRP2 gene single specific site methylation detection, tumor diagnosis reagent and system. The present application firstly uses the methylation of SFRP2 gene single specific site chr4: 153781309 as a biomarker for detecting, predicting or monitoring the preparation of tumor development products, compared with other known methylation sites, which can effectively detect tumor patients. Further, on the basis of the methylation detection of the above site chr4: 153781309, the present application combines the methylation of the specific site and the methylation of other sites of SFRP2 gene, which can significantly improve the detection sensitivity and specificity.

A compound of formula (I) wherein R1, R2, R3, R4, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, L, Ring A, Ring B, Ring C and Ring D are as described herein, a stereoisomer, isotopic variant thereof, or a pharmaceutically acceptable salt or solvate thereof, which is useful as an Arfl inhibitor, pharmaceutical compositions comprising the same and use in the treatment or prevention of a disease associated with Arfl pathway activity, such as cancer or tumor, in a subject, the invention also provides application of the compound in preparation of therapeutic vaccines for retarding tumor development.

The invention belongs to the technical field of biological medicine, and provides an immunotherapy response prediction marker RBM28 and application thereof in combined treatment sensitization, the application is characterized in that the expression level of RBM28 is used as an evaluation index, a TG003 and PD-1 or ATO and PD-1 combined inhibitor is used for in-vitro treatment of esophageal squamous carcinoma tumor cells and mouse models, and the immunotherapy response prediction marker RBM28 can be used for immunotherapy sensitization. The immunotherapy prediction effect of the RBM28 expression level as an evaluation index on the esophageal squamous cell carcinoma and the treatment effect of the TG003 and PD-1 or ATO and PD-1 combined inhibitor on the esophageal squamous cell carcinoma are evaluated; results show that high expression of RBM28 is related to development of various tumors, and RBM28 can be used as an immunotherapy response prediction marker; the inhibitor can be used for jointly treating esophageal squamous cell carcinoma, inhibiting RBM28 phosphorylation, inducing immune activation, enhancing the curative effect of immunotherapy and remarkably reducing the tumor volume so as to achieve the purpose of treating esophageal squamous cell carcinoma.

The invention provides a pH-sensitive fluorescent probe for detecting thionitrous acid and a preparation method and application thereof, the fluorescent probe has good stability, the structural formula is shown in the specification, the fluorescent probe has good selectivity and sensitivity (the detection limit is 415 nM) to HSNO in an acid environment, specific detection of HSNO in HCT-116 cells is achieved, and the fluorescent probe has good application prospects. And the fluorescent probe is applied to fluorescence imaging of HSNO in an HCT-116 colon cancer nude mouse transplanted tumor. Besides, after the HSNO is intravenously injected into the tail of a transplanted tumor nude mouse, the tumor growth is inhibited, and the HSNO level in the tumor tissue is increased, which indicates that the HSNO has the anti-tumor activity, and an effective detection tool is provided for researching the relationship between the HSNO and the tumor development.

The invention is applicable to the technical field of biological medicines, and particularly relates to a reagent for silencing or inhibiting a PRDX6 gene and application of a PRDX6 C47S mutant in induction of ferroptosis of tumor cells. It is found that PRDX6 is combined with GPX4 through a C47 site to form a disulfide bond, membrane transposition of GPX4 protein is promoted, generation of hydroxy fatty acid is enhanced, repair of a peroxide membrane is promoted, membrane peroxidation is reduced, and tumor development is promoted. Targeted silence or inhibition of PRDX6 has significant potential of inhibiting tumor growth. In addition, the invention also finds that the PRDX6C47S mutant can enhance the ferroptosis sensitivity of tumor cells, and has a remarkable anti-tumor effect when being combined with a ferroptosis inducer IKE.

A method for developing one or more morphometric classifiers to identify tumor mutation load (TMB) is disclosed. The method provides a non-invasive method of characterizing TMB that is responsive to and independent of the size of a tumor in the early stage of tumor development. The method allows for cancer treatment for a specific characterization of the cancer the patient may suffer from, thereby achieving more efficient cancer management with much less side effects.

The present disclosure provides compounds of Formula (I) wherein R1, R2, R3, X1, rings A, B and C, as described herein, stereoisomers, isotopic variants, or pharmaceutically acceptable salts or solvates thereof, which are useful as SOAT1 inhibitors, in particular SOAT1 inhibitors, in particular SOAT1 inhibitors. The invention also provides a pharmaceutical composition containing the same and application of the same in treatment or prevention of SOAT1 pathway activity related diseases such as cancers or tumors in subjects, and also provides application of the same in preparation of therapeutic vaccines for retarding tumor development.

Gene amplifications are an oncogenic driver utilized by many forms of cancer in tumor development or treatment relapse. Promoting genomic instability or the proclivity to propagate genomic alterations through acquired defects in DNA repair machinery, replication licensing, or cell cycle control, gene amplifications not only drive oncogenesis, but also afford an opportunity for therapeutic exploitation. Here, CRISPR-Cas9 nickases are disclosed which selectively promote cancer cell death in a gene amplification-dependent manner. For example, CRISPR- Cas9 nickases generate a lethal number of highly toxic single-ended double-strand breaks within the genome of proliferating cancer cells harboring amplified genomic loci during DNA replication. Cas9 nickases may serve as a tumor-selective therapeutic that mitigates the collateral damage observed with conventional chemoradiotherapies and avoids chemoresistance.